Current progress in the development of human immunodeficiency virus vaccines: research and clinical trials.
In spite of extensive prevention programs, the HIV pandemic is still spreading worldwide, particularly in developing countries. AIDS is the leading cause of death in Africa and the fourth cause worldwide. WHO estimates that there are 16000 new cases of HIV infection daily and that 100 million individuals will be infected during the next decade. In spite of the spectacular results of triple therapy, the best strategy for controlling the HIV epidemics remains the development of an efficacious prophylactic vaccine. However, the development of such a vaccine remains a formidable challenge to both the industry and the scientific community (Esparza J. Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet 2000; 355: 2061-6 [1]).
Aventis Pasteur, Campus Mérieux, 1541 Avenue Marcel Mérieux, 69280, Marcy l'Etoile, France. Michel.Klein@aventis.com
M
M
Klein
D016915:AIDS Vaccines / Q000302:isolation & purification*; D000818:Animals; D002985:Clinical Protocols; D002986:Clinical Trials as Topic; D015483:HIV Antibodies / Q000008:administration & dosage; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D018928:Immunity, Mucosal; D007118:Immunoassay; D023421:Models, Animal; D012106:Research / Q000639:trends; D013601:T-Lymphocytes / Q000276:immunology
D016915:AIDS Vaccines; D015483:HIV Antibodies